All In Biotech

Drug Trial Radar · NCT02127398

Stool Transplants to Treat Refractory Clostridium Difficile Colitis

Fecal Microbiota Transplantation in Refractory Clostridium Difficile Colitis

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

77

Planned (sponsor's estimate)

Start

Apr 2016

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It has been shown that restoration of the normal makeup of the bowel bacterial population is the most effective way to treat recurrent colitis due to Clostridium difficile. Restoration of the normal bowel bacterial population is best done by transplanting stool from a healthy donor. The investigators wish to transplant stool from healthy donors to treat recurrent C. difficile colitis by incorporating the stool into capsules that are administered by the oral route.

Conditions

  • Clostridium Difficile Colitis

Interventions

  • fecal microbiotaBiological

    fecal microbiota in capsule form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrent colitis due to Clostridium difficileTime frame: six months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.